These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31296368)

  • 1. Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
    Willis LH; Slentz CA; Johnson JL; Kelly LS; Craig KP; Hoselton AL; Kraus WE
    Am J Cardiol; 2019 Sep; 124(5):655-660. PubMed ID: 31296368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
    Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
    Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
    Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
    Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
    Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
    Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
    Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
    Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
    Rosano GMC; Vitale C; Volterrani M
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study.
    Zweiker R; Aichinger J; Metzler B; Lang I; Wallner E; Delle-Karth G
    Wien Klin Wochenschr; 2019 Apr; 131(7-8):165-173. PubMed ID: 30963332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
    Nguyen E; Coleman CI; Kohn CG; Weeda ER
    Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
    Coleman CI; Freemantle N; Kohn CG
    BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
    Ahmed B; Mondragon J; Sheldon M; Clegg S
    Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
    Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
    Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release ranolazine: critical evaluation of its use in stable angina.
    Truffa AA; Newby LK; Melloni C
    Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.
    Muhlestein JB; Grehan S
    Drugs R D; 2013 Sep; 13(3):207-13. PubMed ID: 23990357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).
    Parikh KS; Coles A; Schulte PJ; Kraus WE; Fleg JL; Keteyian SJ; Piña IL; Fiuzat M; Whellan DJ; O'Connor CM; Mentz RJ
    Am J Cardiol; 2016 Oct; 118(8):1211-1216. PubMed ID: 27561194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
    Kohn CG; Parker MW; Limone BL; Coleman CI
    Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.